For decades, millions of patients have faced a quiet dilemma: accept the muscle pain that statins bring, or abandon the protection those drugs offer against heart attack and stroke. Researchers at McMaster University have now traced the biological roots of that suffering, identifying a chain reaction in which statins disrupt muscle energy production and trigger an immune response that damages tissue. Published in Science Advances, the work suggests that the mechanism causing harm and the mechanism lowering cholesterol may operate independently — a distinction that, if confirmed, could one day
McMaster researchers identify immune pathway behind statin muscle pain
Statin-induced muscle symptoms affect millions of patients, causing pain, weakness, and exercise intolerance that leads some to discontinue lifesaving medication.
The side effects and the benefits may operate through separate pathways
Mark
So the basic problem is that statins work, but they hurt. People stop taking them because of the pain. That's the human cost here?
Mimi
Exactly. Between 7 and 29 percent of statin users experience muscle symptoms—pain, weakness, exercise intolerance. For some, it's severe enough that they discontinue the medication entirely, which means they lose the cardiovascular protection.
Luke
That's a wide range. Seven to 29 percent. Do we know why the estimates vary so much?
Mimi
The source doesn't specify, but it likely reflects differences in how studies measure symptoms, which patient populations they studied, and which statins were used. Different statins may have different side effect profiles.
Mark
And what did McMaster actually find? What's the mechanism?
Mimi
Statins disrupt how muscle cells produce energy. That metabolic disruption triggers an immune response inside the cells, which then damages the muscle tissue. When they blocked the immune response in their experiments, they prevented most of the damage.
Luke
In their experiments. Muscle cells and mouse models. That's important to note—we're not at the patient stage yet.
Mimi
Right. This is foundational science. But the exciting part is that the cholesterol-lowering mechanism appears to be separate from the muscle-damage mechanism.
Mark
So theoretically, you could design a drug that blocks the immune response without affecting cholesterol?
Mimi
That's the hypothesis. If the pathways are truly independent, yes. But that's still speculative at this stage.
Luke
And how far away is that therapy? The source says additional research is needed. It doesn't give a timeline.
Mimi
No timeline. This is early-stage discovery. The researchers have identified potential targets for future drug development, but translating that into a therapy for patients is years away, probably.
Mark
Still, for someone taking statins and suffering muscle pain, this is hopeful news.
Mimi
It is. It means the problem has a biological explanation, and that explanation points toward a solution.
O Pulso
- Between 7 and 29 percent of statin users experience muscle pain and weakness severe enough that some stop taking medication proven to prevent early death.
- McMaster researchers discovered that statins interfere with how muscle cells generate energy, setting off an internal immune response that actively damages muscle tissue.
- Critically, blocking that immune response in laboratory experiments prevented much of the muscle damage without disrupting the drug's cholesterol-lowering function.
- The apparent separation of these two pathways suggests future therapies could be engineered to preserve cardiovascular protection while eliminating the side effects that drive patients away.
- The findings remain in early stages, with further research required before any new treatment reaches patients — but the direction is now visible where before there was none.
For decades, millions of patients have faced a quiet dilemma: accept the muscle pain that statins bring, or abandon the protection those drugs offer against heart attack and stroke. Researchers at McMaster University have now traced the biological roots of that suffering, identifying a chain reaction in which statins disrupt muscle energy production and trigger an immune response that damages tissue. Published in Science Advances, the work suggests that the mechanism causing harm and the mechanism lowering cholesterol may operate independently — a distinction that, if confirmed, could one day allow medicine to offer the benefit without the burden.
Statins have saved countless lives by lowering cholesterol and reducing the risk of heart attack and stroke, yet for a significant share of the millions who take them, the drugs carry a daily cost: muscle pain, weakness, and an exhaustion that makes movement feel punishing. Some patients ultimately choose relief over protection, stopping their medication entirely. For years, medicine knew this was happening but could not explain why.
A team at McMaster University, led by senior author Jonathan Schertzer and first authors Nazli Robin and Nicole Barra, has now identified the mechanism. Working with muscle cells and mouse models, the researchers found that statins disrupt the way muscles produce energy. That metabolic disruption, in turn, triggers an immune response inside the cells themselves — one that proceeds to damage the surrounding tissue. When the team blocked this immune response in their experiments, much of the muscle damage was prevented.
What makes the finding particularly significant is what it implies about the drug's two effects. The pathway driving muscle damage appears to be separate from the pathway that lowers cholesterol. If that separation holds, it opens the possibility of designing therapies that preserve the cardiovascular benefit while neutralizing the side effect that pushes patients to quit.
The research, published in Science Advances, is preliminary, and translating it into clinical treatments will require further work. But for patients caught between protecting their hearts and living without pain, the discovery marks a meaningful turn: the biology of statin intolerance is no longer a mystery, and the search for a solution now has a map.
Statins are among the most prescribed medications in the world. They lower cholesterol, reduce the risk of heart attack and stroke, and have saved countless lives. But for millions of people who take them, the drugs exact a price: muscle pain, weakness, a loss of stamina that makes exercise feel impossible. Some patients stop taking the medication altogether, trading the protection against cardiovascular disease for relief from the daily ache. For decades, doctors and researchers knew this happened. They did not know why.
Now a team at McMaster University has identified the biological mechanism behind statin-induced muscle damage, work published this week in Science Advances. The discovery suggests that the side effects and the benefits may operate through separate pathways—which means, theoretically, future drugs could preserve one while eliminating the other.
The problem is widespread. Between 7 and 29 percent of people who take statins experience muscle symptoms. That translates to millions of patients worldwide. Jonathan Schertzer, a professor in McMaster's Department of Biochemistry and Biomedical Sciences and the senior author of the study, framed the dilemma plainly: statins are among the most effective medications available for reducing cardiovascular disease risk and preventing early death, yet muscle side effects push some patients to reduce their dose or abandon treatment entirely. The researchers wanted to understand the mechanism and explore whether the two effects could be separated.
Led by first authors Nazli Robin and Nicole Barra, the team conducted experiments using muscle cells and mouse models. They found that statins disrupt the way muscle cells generate energy. This metabolic disruption triggers an immune response within the cells themselves, which then damages muscle tissue. Crucially, when the researchers blocked this immune response in their experiments, they were able to prevent much of the muscle damage.
The finding challenges long-held assumptions about how statin side effects develop. More importantly, it revealed something unexpected: the mechanism driving muscle damage appears to be distinct from the mechanism that lowers cholesterol. This separation opens a door. If the two pathways are truly independent, then a future therapy could target the immune response without interfering with the drug's cardiovascular benefits.
Schertzer emphasized the significance of this discovery. The research identifies a clear link between changes in muscle metabolism and the triggering of an immune response, providing new insight into how inflammation can contribute to drug side effects more broadly. The team has identified several potential targets for future drug development aimed at preventing statin intolerance.
The work remains preliminary. Additional research will be needed before these findings can be translated into therapies for patients. But for the millions of people who currently face the choice between cardiovascular protection and muscular comfort, the direction is clear. The pathway to safer, more tolerable statins has begun to emerge.
Citações Notáveis
Muscle side effects lead some people to reduce their dose or stop taking the medication altogether. We wanted to understand why this happens and whether it might be possible to separate the side effects from the benefits.— Jonathan Schertzer, McMaster University
The mechanism causing muscle side effects appears to be separate from the mechanism that lowers cholesterol. That suggests it may one day be possible to target the side effects without interfering with the cardiovascular benefits.— Jonathan Schertzer, McMaster University
Quer a matéria completa?
Leia o original em Medical Xpress ↗
Economy & Finance